Goethe University Frankfurt

At the Epilepsy Center Frankfurt Rhine-Main, investigators are focusing on Tuberous Sclerosis Complex–related seizures, exploring new options to improve long‑term control for both children and adults.

• Long‑term safety and tolerability evaluation
• Adjunctive therapy with ganaxolone
• Inclusion of pediatric and adult populations
• Monitoring of seizure frequency and quality of life

The program underscores Goethe University Frankfurt’s commitment to advancing treatments for nervous system disorders.

Researchers are evaluating a precision approach for patients with H3 K27M‑mutant diffuse glioma, aiming to enhance outcomes after standard radiotherapy.

• Molecularly driven drug assessment
• Post‑radiation maintenance strategy
• Exploration of survival benefit
• Integration of biomarker analysis

The study highlights the site’s expertise in neuro‑oncology within the broader neoplasm therapeutic area.

A novel immunotherapy trial is testing the CVGBM vaccine in patients who have undergone surgery for glioblastoma or astrocytoma, seeking to prevent tumor recurrence.

• Dose‑escalation safety assessment
• Evaluation of immune response activation
• Post‑surgical adjuvant treatment model
• Comprehensive adverse‑event monitoring

This effort reflects the center’s dedication to innovative cancer therapies within the neoplasms research portfolio.